TY - JOUR
T1 - Establishment of the Western Japan Psoriasis Registry and first cross-sectional analysis of registered patients
AU - Western Japan Inflammatory Disease Research Group
AU - Tsuruta, Noriko
AU - Imafuku, Shinichi
AU - Yamaguchi, Kazuki
AU - Katayama, Eri
AU - Nakama, Takekuni
AU - Higashi, Yuko
AU - Yonekura, Kentaro
AU - Hashimoto, Aki
AU - Kuwashiro, Maki
AU - Koike, Yuta
AU - Murota, Hiroyuki
AU - Miyagi, Takuya
AU - Takahashi, Kenzo
AU - Harada, Kayo
AU - Saito, Kanami
AU - Hatano, Yutaka
AU - Matsuzaka, Yuki
AU - Ikeda, Kenta
AU - Morizane, Shin
AU - Kikuchi, Satoko
AU - Ota, Masataka
AU - Kaneko, Sakae
AU - Nakahara, Takeshi
AU - Furue, Masutaka
AU - Ito, Kotaro
AU - Yanase, Tetsuji
AU - Sasaki, Natsuko
AU - Okada, Etsuko
AU - Saruwatari, Hiroshi
AU - Ohata, Chika
AU - Okazaki, Fusako
AU - Sugita, Kazunari
AU - Ohyama, Bungo
N1 - Funding Information:
The WJPR is run by a Non‐Profit Organization Western Japan Inflammatory Skin Disease Research Group, and this NPO is supported by precious funding support from Japanese Society for Psoriasis Research, Amgen, Abbvie, Eisai, Taiho Yakuhin Kogyo, KyowaKirin, Maruho, and Sun Pharma.
Publisher Copyright:
© 2021 Japanese Dermatological Association
PY - 2021/11
Y1 - 2021/11
N2 - The efficacy and safety of new psoriatic treatments are confirmed in clinical trials, but such clinical trial data are limited by the number and heterogeneity of patients. Furthermore, the prevalence and characteristics of psoriasis differ among racial groups. Therefore, it is important to obtain real-world evidence in specific regions. To identify the optimal systemic treatment for psoriatic patients in Western Japan, we established the Western Japan Psoriasis Registry (WJPR). This registry is led by a neutral physicians’ league associated with university hospitals, general hospitals, and clinics that specialize in treatment of psoriasis. Systemically treated psoriatic patients who provided written informed consent were enrolled, and data were collected on their background information, several patient-reported outcomes, dermatologists’ objective evaluations, and treatment regimens. Patient enrollment began in 2019, and 1394 patients had been recruited by the end of 2020. The prevalence of psoriatic arthritis was 27.2% and that of pustular psoriasis was 7.5%. The mean body mass index was 24.1 kg/m2, and 12% of patients had severe obesity (body mass index ≥30 kg/m2). Major comorbidities were hypertension (35.0%), diabetes (14.1%), and hyperlipidemia (12.2%). Serological data showed that hepatitis B virus surface antigen, anti-hepatitis B virus core antibody, anti-hepatitis C virus antibody, and human T-cell leukemia virus type 1 antibody were detected in 1.1%, 18.0%, 3.1%, and 3.7% of patients, respectively. The most frequently used small-molecule-systemic intervention was apremilast (18.0%), followed by methotrexate (7.7%), etretinate (4.2%), and cyclosporin (3.7%). The most frequently used biologics were interleukin (IL)-17 inhibitors (31.8%), followed by IL-23 inhibitors (including IL-12/23 inhibitors) (26.7%), and tumor necrosis factor inhibitors (11.1%). The WJPR is the first Japanese prospective observational cohort of psoriatic patients. Annual WJPR updates may provide the incidences of comorbidities such as cardiovascular events or onset of arthritis in systemically treated patients, identify rare complications, and identify the optimal treatment regimens for various psoriatic patients.
AB - The efficacy and safety of new psoriatic treatments are confirmed in clinical trials, but such clinical trial data are limited by the number and heterogeneity of patients. Furthermore, the prevalence and characteristics of psoriasis differ among racial groups. Therefore, it is important to obtain real-world evidence in specific regions. To identify the optimal systemic treatment for psoriatic patients in Western Japan, we established the Western Japan Psoriasis Registry (WJPR). This registry is led by a neutral physicians’ league associated with university hospitals, general hospitals, and clinics that specialize in treatment of psoriasis. Systemically treated psoriatic patients who provided written informed consent were enrolled, and data were collected on their background information, several patient-reported outcomes, dermatologists’ objective evaluations, and treatment regimens. Patient enrollment began in 2019, and 1394 patients had been recruited by the end of 2020. The prevalence of psoriatic arthritis was 27.2% and that of pustular psoriasis was 7.5%. The mean body mass index was 24.1 kg/m2, and 12% of patients had severe obesity (body mass index ≥30 kg/m2). Major comorbidities were hypertension (35.0%), diabetes (14.1%), and hyperlipidemia (12.2%). Serological data showed that hepatitis B virus surface antigen, anti-hepatitis B virus core antibody, anti-hepatitis C virus antibody, and human T-cell leukemia virus type 1 antibody were detected in 1.1%, 18.0%, 3.1%, and 3.7% of patients, respectively. The most frequently used small-molecule-systemic intervention was apremilast (18.0%), followed by methotrexate (7.7%), etretinate (4.2%), and cyclosporin (3.7%). The most frequently used biologics were interleukin (IL)-17 inhibitors (31.8%), followed by IL-23 inhibitors (including IL-12/23 inhibitors) (26.7%), and tumor necrosis factor inhibitors (11.1%). The WJPR is the first Japanese prospective observational cohort of psoriatic patients. Annual WJPR updates may provide the incidences of comorbidities such as cardiovascular events or onset of arthritis in systemically treated patients, identify rare complications, and identify the optimal treatment regimens for various psoriatic patients.
KW - Japan
KW - cohort
KW - patient registry
KW - prospective study
KW - psoriasis
UR - http://www.scopus.com/inward/record.url?scp=85114763107&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114763107&partnerID=8YFLogxK
U2 - 10.1111/1346-8138.16092
DO - 10.1111/1346-8138.16092
M3 - Article
C2 - 34427347
AN - SCOPUS:85114763107
VL - 48
SP - 1709
EP - 1718
JO - Journal of Dermatology
JF - Journal of Dermatology
SN - 0385-2407
IS - 11
ER -